Docoh
Loading...

WCRX Warner Chilcott

Filed: 25 May 18, 5:00pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form10-Q/A

(Amendment No. 1 to Form10-Q)

 

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                    to                    

 

Commission

File Number

 

Exact name of registrant as specified in its charter,

principal office and address and telephone  number

 

State of incorporation

or organization

  

I.R.S. Employer

Identification No.

001-36867 

Allergan plc

Clonshaugh Business and Technology Park

Coolock, Dublin, D17 E400, Ireland

(862)261-7000

 Ireland  98-1114402
001-36887 

Warner Chilcott Limited

Canon’s Court

22 Victoria Street

Hamilton HM 12

Bermuda

(441)295-2244

 Bermuda  98-0496358

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

 

Allergan plc  YES    ☒  NO    ☐
Warner Chilcott Limited  YES    ☒  NO    ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Allergan plc  YES    ☒  NO    ☐
Warner Chilcott Limited  YES    ☒  NO    ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” inRule 12b-2 of the Exchange Act. (Check one):

 

Allergan plc Large accelerated filer   Accelerated filer  
 Non-accelerated filer (Do not check if a smaller reporting company)   Smaller reporting company  
 Emerging growth company     
Warner Chilcott Limited Large accelerated filer   Accelerated filer  
 Non-accelerated filer (Do not check if a smaller reporting company)   Smaller reporting company  
 Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined inRule 12b-2 of the Act).

 

Allergan plc  YES    ☐  NO    ☒
Warner Chilcott Limited  YES    ☐  NO    ☒

Number of shares of Allergan plc’s Ordinary Shares outstanding on April 27, 2018: 339,063,627. There is no trading market for securities of Warner Chilcott Limited, all of which are indirectly wholly owned by Allergan plc.

This Quarterly Report on Form10-Q is a combined report being filed separately by two different registrants: Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc. The information in this Quarterly Report on Form10-Q is equally applicable to Allergan plc and Warner Chilcott Limited, except where otherwise indicated. Warner Chilcott Limited meets the conditions set forth in General Instruction H(1)(a) and (b) of Form10-Q and, to the extent applicable, is therefore filing this form with a reduced disclosure format.

 

 

 


Explanatory Note

This Amendment No. 1 to Form10-Q (this “Amendment”) amends the Quarterly Report on Form10-Q of Allergan plc and Warner Chilcott Limited for the quarterly period ended March 31, 2018, originally filed with the Securities and Exchange Commission (the “SEC”) on May 3, 2018 (the “Original Form10-Q”). Allergan plc and Warner Chilcott Limited file this Amendment solely for the purpose of filing Exhibit 10.2, the material terms of which were described on a Current Report on Form 8-K filed by Allergan plc on February 5, 2018, and which was inadvertently omitted from the Original Form10-Q. Pursuant to Rule12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment restates in its entirety Part II, Item 6 and contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed herewith.

Other than adding Exhibit 10.2, no other changes have been made to the Original Form10-Q. This Amendment does not reflect events that may have occurred subsequent to the filing date of the Original Form10-Q, and does not modify or update in any way any other disclosure made in the Original Form10-Q.


PART II. OTHER INFORMATION

 

ITEM 6.EXHIBITS

 

Exhibit  Description
10.1#**  Separation Agreement by and between Robert A. Stewart and Allergan, Inc. dated as of March 8, 2018.
10.2#*  Offer Letter from Allergan plc to Matthew M. Walsh, dated January 30, 2018.
31.1*  Certification of Chief Executive Officer pursuant to Rule13a-14a of the Securities Exchange Act of 1934.
31.2*  Certification of Chief Financial Officer pursuant to Rule13a-14a of the Securities Exchange Act of 1934.
101.INS**  XBRL Instance Document.
101.SCH**  XBRL Taxonomy Extension Scheme Document.
101.CAL**  XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF**  XBRL Taxonomy Extension Label Definition Document.
101.LAB**  XBRL Taxonomy Extension Label Linkbase Document.
101.PRE**  XBRL Taxonomy Extension Presentation Linkbase Document.

 

#Indicates a management contract or compensatory plan or arrangement.
*Filed herewith.
**Filed as an exhibit to the Original Form 10-Q.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 25, 2018.

 

ALLERGAN PLC

WARNER CHILCOTT LIMITED

By: 

/s/ Matthew M. Walsh

Name: Matthew M. Walsh
Title: 

Chief Financial Officer

(Principal Financial Officer)

By: 

/s/ James C. D’Arecca

Name: James C. D’Arecca
Title: 

Chief Accounting Officer

(Principal Accounting Officer)